183 related articles for article (PubMed ID: 2571187)
1. Synergism between HIV gp120 and gp120-specific antibody in blocking human T cell activation.
Mittler RS; Hoffmann MK
Science; 1989 Sep; 245(4924):1380-2. PubMed ID: 2571187
[TBL] [Abstract][Full Text] [Related]
2. Recognition of HIV glycoprotein gp120 by T cells. Role of monocyte CD4 in the presentation of gp120.
Siliciano RF; Knall C; Lawton T; Berman P; Gregory T; Reinherz EL
J Immunol; 1989 Mar; 142(5):1506-11. PubMed ID: 2537355
[TBL] [Abstract][Full Text] [Related]
3. CD4+ lymphocyte function with early human immunodeficiency virus infection.
Gurley RJ; Ikeuchi K; Byrn RA; Anderson K; Groopman JE
Proc Natl Acad Sci U S A; 1989 Mar; 86(6):1993-7. PubMed ID: 2564677
[TBL] [Abstract][Full Text] [Related]
4. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization.
Ho DD; Kaplan JC; Rackauskas IE; Gurney ME
Science; 1988 Feb; 239(4843):1021-3. PubMed ID: 2830667
[TBL] [Abstract][Full Text] [Related]
5. CD4 epitope masking by gp120/anti-gp120 antibody complexes. A potential mechanism for CD4+ cell function down-regulation in AIDS patients.
Amadori A; De Silvestro G; Zamarchi R; Veronese ML; Mazza MR; Schiavo G; Panozzo M; De Rossi A; Ometto L; Mous J
J Immunol; 1992 May; 148(9):2709-16. PubMed ID: 1374095
[TBL] [Abstract][Full Text] [Related]
6. Certain human Gp120-HIV antibodies react with anti-CD4 antibodies.
Lundin K; Karlsson A; Nygren A; Löfström A; Gigliotti D; Wigzell H
Scand J Immunol; 1988 Jan; 27(1):113-7. PubMed ID: 2829345
[TBL] [Abstract][Full Text] [Related]
7. The CD4 antigen: physiological ligand and HIV receptor.
Sattentau QJ; Weiss RA
Cell; 1988 Mar; 52(5):631-3. PubMed ID: 2830988
[No Abstract] [Full Text] [Related]
8. Inhibitory influences of envelope glycoproteins of HIV-1 on normal immune responses.
Chirmule N; Kalyanaraman V; Oyaizu N; Pahwa S
J Acquir Immune Defic Syndr (1988); 1988; 1(5):425-30. PubMed ID: 2851650
[TBL] [Abstract][Full Text] [Related]
9. Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies.
Dowbenko D; Nakamura G; Fennie C; Shimasaki C; Riddle L; Harris R; Gregory T; Lasky L
J Virol; 1988 Dec; 62(12):4703-11. PubMed ID: 2460639
[TBL] [Abstract][Full Text] [Related]
10. Characterization of CD4 glycoprotein determinant-HIV envelope protein interactions: perspectives for analog and vaccine development.
Farrar WL; Harel-Bellan A; Ferris DK
Crit Rev Immunol; 1988; 8(4):315-39. PubMed ID: 2850890
[TBL] [Abstract][Full Text] [Related]
11. Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera.
Koup RA; Sullivan JL; Levine PH; Brewster F; Mahr A; Mazzara G; McKenzie S; Panicali D
J Virol; 1989 Feb; 63(2):584-90. PubMed ID: 2536094
[TBL] [Abstract][Full Text] [Related]
12. The role of the CD4 antigen in HIV infection and immune pathogenesis.
Sattentau QJ
AIDS; 1988; 2 Suppl 1():S11-6. PubMed ID: 2852500
[No Abstract] [Full Text] [Related]
13. Inhibition of functional properties of tetanus antigen-specific T-cell clones by envelope glycoprotein GP120 of human immunodeficiency virus.
Chirmule N; Kalyanaraman VS; Oyaizu N; Slade HB; Pahwa S
Blood; 1990 Jan; 75(1):152-9. PubMed ID: 1967213
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection.
Weinhold KJ; Lyerly HK; Stanley SD; Austin AA; Matthews TJ; Bolognesi DP
J Immunol; 1989 May; 142(9):3091-7. PubMed ID: 2468713
[TBL] [Abstract][Full Text] [Related]
15. Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men.
Krohn K; Robey WG; Putney S; Arthur L; Nara P; Fischinger P; Gallo RC; Wong-Staal F; Ranki A
Proc Natl Acad Sci U S A; 1987 Jul; 84(14):4994-8. PubMed ID: 2440037
[TBL] [Abstract][Full Text] [Related]
16. Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation.
Hildreth JE; Orentas RJ
Science; 1989 Jun; 244(4908):1075-8. PubMed ID: 2543075
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.
Skinner MA; Langlois AJ; McDanal CB; McDougal JS; Bolognesi DP; Matthews TJ
J Virol; 1988 Nov; 62(11):4195-200. PubMed ID: 2845130
[TBL] [Abstract][Full Text] [Related]
18. Antibody-dependent cellular cytotoxicity is directed against both the gp120 and gp41 envelope proteins of HIV.
Evans LA; Thomson-Honnebier G; Steimer K; Paoletti E; Perkus ME; Hollander H; Levy JA
AIDS; 1989 May; 3(5):273-6. PubMed ID: 2548535
[TBL] [Abstract][Full Text] [Related]
19. Harming and protecting responses to HIV.
Lanzavecchia A
Res Immunol; 1989 Jan; 140(1):99-103; discussion 123-4. PubMed ID: 2567046
[No Abstract] [Full Text] [Related]
20. Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160.
Berman PW; Riddle L; Nakamura G; Haffar OK; Nunes WM; Skehel P; Byrn R; Groopman J; Matthews T; Gregory T
J Virol; 1989 Aug; 63(8):3489-98. PubMed ID: 2545918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
